Raymond James Financial
ANIX icon

Raymond James Financial’s Anixa Biosciences ANIX Stock Holding History

Raymond James Financial’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,260
Closed -$4.16K – 5037
2025
Q2 		$4.16K Buy
+1,260
New +$3.6K ﹤0.01% 6227

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James Financial's ANIX Position: Q3 2025 in Review

Raymond James Financial sold out of Anixa Biosciences (ANIX) in Q3 2025, closing a stake of 1,260 shares — an estimated $4.16K sold.

Raymond James Financial first reported a position in ANIX in Q2 2025 and held it in 1 quarter. The position peaked at $4.16K in Q2 2025. 66 funds tracked by Wall St. Rank hold ANIX as of Q3 2025.

  • Raymond James Financial reported no remaining Anixa Biosciences position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1,260 Anixa Biosciences shares in Q3 2025, an estimated $4.16K.
  • Raymond James Financial first reported a position in Anixa Biosciences in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Anixa Biosciences position peaked at $4.16K in Q2 2025.
  • 66 funds tracked by Wall St. Rank held Anixa Biosciences as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.